A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Status:
Recruiting
Trial end date:
2023-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of
JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and and preliminary signs of
clinical activity at the RP2D(s) in Part 2 (Dose Expansion).